Free Trial
→ Rigged election? (From Porter & Company) (Ad) Free RGRX Stock Alerts

RegeneRx Biopharmaceuticals (RGRX) Short Interest Ratio & Short Volume

RegeneRx Biopharmaceuticals logo
$0.0014
0.00 (0.00%)
(As of 11/4/2024 ET)
Compare

RegeneRx Biopharmaceuticals Short Interest Data

RegeneRx Biopharmaceuticals (RGRX) has a short interest of 100 shares. This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 1,174 shares to cover all short positions.

Current Short Interest
100 shares
Previous Short Interest
100 shares
Change Vs. Previous Month
No Change
Dollar Volume Sold Short
$0.14
Short Interest Ratio
0.1 Days to Cover
Last Record Date
October 15, 2024
Outstanding Shares
1,510,000 shares
Percentage of Shares Shorted
0.01%
Today's Trading Volume
8 shares
Average Trading Volume
1,174 shares
Today's Volume Vs. Average
1%
Short Selling RegeneRx Biopharmaceuticals?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

RGRX Short Interest Over Time

RGRX Days to Cover Over Time

RGRX Percentage of Float Shorted Over Time

RegeneRx Biopharmaceuticals Short Interest History

Export to Excel
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/15/2024100 shares $0.14 No ChangeN/A0.1 $0.00
9/30/2024100 shares $0.14 No ChangeN/A1 $0.00
9/15/2024100 shares $0.14 No ChangeN/A0.1 $0.00
8/31/2024100 shares $0.14 No ChangeN/A0.3 $0.00
8/15/2024100 shares $5.22 No ChangeN/A0.3 $0.05
7/31/2024100 shares $0.14 No ChangeN/A0.3 $0.00
7/15/2024100 shares $0.14 No ChangeN/A1 $0.00
6/30/2024100 shares $0.14 No ChangeN/A1 $0.00
6/15/2024100 shares $0.14 No ChangeN/A0 $0.00
5/31/2024100 shares $0.14 No ChangeN/A1 $0.00
5/15/2024100 shares $0.14 No ChangeN/A1 $0.00
4/30/2024100 shares $0.14 No ChangeN/A1 $0.00
4/15/2024100 shares $5.22 No ChangeN/A1 $0.05
3/31/2024100 shares $0.14 No ChangeN/A0.2 $0.00
3/15/2024100 shares $0.12 No ChangeN/A0.2 $0.00
2/29/2024100 shares $0.12 No ChangeN/A1 $0.00
2/15/2024100 shares $0.12 No ChangeN/A1 $0.00
1/15/2024100 shares $0.12 No ChangeN/A0.3 $0.00
12/31/2023100 shares $0.12 No ChangeN/A0 $0.00
12/15/2023100 shares $0.04 No ChangeN/A0.3 $0.00
11/30/2023100 shares $0.09 No ChangeN/A0.2 $0.00
10/15/2023600 shares $6.51 -92.9%N/A0 $0.01
9/30/20238,500 shares $144.50 -28.0%N/A0.1 $0.02
9/15/202311,800 shares $251.34 -39.2%N/A0.1 $0.02
8/31/202319,400 shares $310.40 -22.7%N/A0.1 $0.02
8/15/202325,100 shares $710.33 +13.6%N/A0.1 $0.03
7/31/202322,100 shares $559.13 +3,583.3%N/A0.1 $0.03
7/15/2023600 shares $21.90 -25.0%N/A0 $0.04
6/30/2023800 shares $21.28 -96.3%N/A0 $0.03
6/15/202321,500 shares $655.75 +2.9%N/A0.1 $0.03
5/31/202320,900 shares $833.91 +945.0%N/A0.1 $0.04
5/15/20232,000 shares $115.00 +11.1%N/A0 $0.06
4/30/20231,800 shares $126.00 -98.4%N/A0 $0.07
4/15/2023108,800 shares $3,264.00 +29.8%N/A0.1 $0.03
3/31/202383,800 shares $8,799.00 -0.2%N/A2 $0.11
3/15/202384,000 shares $9,979.20 -0.5%N/A5.4 $0.12
2/28/202384,400 shares $11,104.59 -0.2%N/A3.2 $0.13
2/15/202384,600 shares $9,509.04 +0.7%N/A1.6 $0.11
1/31/202384,000 shares $12,591.60 +0.1%N/A2.5 $0.15
1/15/202383,900 shares $12,576.61 +0.1%N/A1.5 $0.15
The Final Frontier (Ad)

And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.

Here’s the full story for you.
12/30/202283,800 shares $11,639.82 -0.5%N/A1 $0.14
12/15/202284,200 shares $11,788.00 No ChangeN/A0.9 $0.14
11/30/202284,200 shares $13,472.00 +0.5%N/A3.4 $0.16
11/15/202283,800 shares $14,518.35 No ChangeN/A1.1 $0.17
10/31/202283,800 shares $14,246.00 -0.4%N/A1.5 $0.17
10/15/202284,100 shares $14,952.98 +0.4%N/A3.8 $0.18
9/30/202283,800 shares $11,732.00 No ChangeN/A3.1 $0.14
9/15/202283,800 shares $14,329.80 -1.2%N/A1.8 $0.17
8/31/202284,800 shares $13,652.80 +1.1%N/A1.7 $0.16
8/15/202283,900 shares $15,102.00 -18.4%N/A1.5 $0.18
7/31/2022102,800 shares $19,018.00 -5.6%N/A1.7 $0.19
7/15/2022108,900 shares $20,658.33 +7.2%N/A1.3 $0.19
6/30/2022101,600 shares $15,748.00 +12.3%N/A1.1 $0.16
6/15/202290,500 shares $14,027.50 -15.9%N/A4 $0.16
5/31/2022107,600 shares $19,368.00 +5.8%N/A1.5 $0.18
5/15/2022101,700 shares $19,323.00 +15.3%N/A1 $0.19
4/30/202288,200 shares $13,671.00 -1.1%N/A2 $0.16
4/15/202289,200 shares $15,940.04 -35.4%N/A0.8 $0.18
3/31/2022138,000 shares $24,840.00 +35.2%N/A1.2 $0.18
3/15/2022102,100 shares $21,185.75 -1.7%N/A0.7 $0.21
2/28/2022103,900 shares $27,014.00 +9.1%N/A0.4 $0.26
2/15/202295,200 shares $25,704.00 +561.1%N/A0.4 $0.27
1/31/202214,400 shares $3,924.00 -26.5%N/A0.1 $0.27
1/15/202219,600 shares $3,547.60 +71.9%N/A0.2 $0.18
12/31/202111,400 shares $1,824.00 -6.6%N/A0 $0.16
12/15/202112,200 shares $1,875.14 +14.0%N/A0 $0.15
11/30/202110,700 shares $2,138.93 -20.2%N/A0.1 $0.20
11/15/202113,400 shares $2,211.00 -2.9%N/A0.1 $0.17
10/29/202113,800 shares $2,482.62 +13.1%N/A0 $0.18
10/15/202112,200 shares $2,220.40 -56.6%N/A0.1 $0.18
9/30/202128,100 shares $4,636.50 -66.2%N/A0.1 $0.17
9/15/202183,100 shares $16,620.00 +6,292.3%N/A0.5 $0.20
8/31/20211,300 shares $284.70 -84.0%N/A0 $0.22
8/13/20218,100 shares $2,065.50 +636.4%N/A0.1 $0.26
7/30/20211,100 shares $294.25 -85.5%N/A0 $0.27
7/15/20217,600 shares $2,204.00 +442.9%N/A0.1 $0.29
6/30/20211,400 shares $379.40 -67.4%N/A0 $0.27
6/15/20214,300 shares $1,236.25 +43.3%N/A0 $0.29
5/28/20213,000 shares $907.47 -45.5%N/A0 $0.30
5/14/20215,500 shares $1,160.23 -66.3%N/A0.1 $0.21
4/30/202116,300 shares $3,586.00 +270.5%N/A0.1 $0.22
4/15/20214,400 shares $859.98 +91.3%N/A0 $0.20
3/31/20212,300 shares $632.39 -80.5%N/A0 $0.27
3/15/202111,800 shares $7,906.00 -37.9%N/A0.1 $0.67
2/26/202119,000 shares $13,775.00 +475.8%N/A0.1 $0.73
2/12/20213,300 shares $1,947.00 -88.3%N/A0 $0.59
1/29/202128,100 shares $13,038.40 +1,121.7%N/A0.1 $0.46
1/15/202113,000 shares $6,370.00 +7.4%N/A0.1 $0.49
12/31/202026,400 shares $12,513.60 +103.1%N/A0.1 $0.47
12/15/202013,000 shares $6,577.35 +7.4%N/A0.1 $0.51
The Final Frontier (Ad)

And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.

Here’s the full story for you.
11/30/202012,100 shares $7,139.00 +348.2%N/A0.1 $0.59
11/15/20202,700 shares $1,458.00 -87.0%N/A0 $0.54
10/30/202020,800 shares $11,752.00 +116.7%N/A0.2 $0.57
10/15/20209,600 shares $4,310.40 +108.7%N/A0.1 $0.45
9/30/20204,600 shares $1,830.80 +283.3%N/A0 $0.40
9/15/20201,200 shares $715.20 -42.9%N/A0 $0.60
8/31/20202,100 shares $1,197.00 -12.5%N/A0 $0.57
8/14/20202,400 shares $1,608.00 -82.9%N/A0 $0.67
7/31/202014,000 shares $5,320.00 -52.5%N/A0.1 $0.38
7/15/202029,500 shares $11,505.00 +1,538.9%N/A0.2 $0.39
6/30/20201,800 shares $567.36 -64.0%N/A0 $0.32
6/15/20205,000 shares $1,450.50 -75.5%N/A0 $0.29
5/29/202020,400 shares $5,916.00 -2.4%N/A0.3 $0.29
5/15/202020,900 shares $4,932.40 +44.1%N/A0.3 $0.24
4/30/202014,500 shares $3,741.00 +866.7%N/A0.3 $0.26
4/15/20201,500 shares $444.00 +150.0%N/A0 $0.30
3/31/2020600 shares $162.00 -94.3%N/A0 $0.27
3/13/202010,500 shares $2,100.00 +228.1%N/A0.1 $0.20
2/28/20203,200 shares $800.00 -54.9%N/A0 $0.25
2/14/20207,100 shares $1,349.00 +208.7%N/A0 $0.19
1/31/20202,300 shares $598.00 -94.1%N/A0 $0.26
1/15/202038,700 shares $7,159.50 +6,350.0%N/A0.8 $0.19
12/31/2019600 shares $168.00 -94.1%N/A0 $0.28

RGRX Short Interest - Frequently Asked Questions

What is RegeneRx Biopharmaceuticals' current short interest?

Short interest is the volume of RegeneRx Biopharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 15th, investors have sold 100 shares of RGRX short. Learn More on RegeneRx Biopharmaceuticals' current short interest.

How does RegeneRx Biopharmaceuticals' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to RegeneRx Biopharmaceuticals: eFFECTOR Therapeutics, Inc. (16.84%), IMV Inc. (1.31%), Sienna Biopharmaceuticals, Inc. (0.00%), Alvotech (0.07%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks.

What does it mean to sell short RegeneRx Biopharmaceuticals stock?

Short selling RGRX is an investing strategy that aims to generate trading profit from RegeneRx Biopharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against RegeneRx Biopharmaceuticals?

A short squeeze for RegeneRx Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RGRX, which in turn drives the price of the stock up even further.

How often is RegeneRx Biopharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RGRX, twice per month. The most recent reporting period available is October, 15 2024.



Related Companies
Short Interest Tools

This page (OTCMKTS:RGRX) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners
2 sentences that change everything you THOUGHT you knew about trading
If you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...
Investing Daily | Sponsored
Bill Gates’s Next Big AI Bet: Stargate
In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...
Brownstone Research | Sponsored
Election warning coming true…
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
Porter & Company | Sponsored
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...
Crypto Swap Profits | Sponsored
Tim Sykes’ Urgent Trade Alert: “Make this move now”
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...
Timothy Sykes | Sponsored
A Totally New ‘Income Coin’
Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...
Crypto 101 Media | Sponsored
The centerpiece of Trump’s crypto’s masterplan …
Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...
Weiss Ratings | Sponsored
A new way to play the AI boom (act before November 19)
There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...
Behind the Markets | Sponsored